SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

被引：0
|
作者：
Owonikoko, T. [1 ]
Dahlberg, S. [2 ]
Sica, G. [3 ]
Poirier, J. [4 ]
Byers, L. [5 ]
Rudin, C. [6 ]
Wistuba, I. [7 ]
Ramalingam, S. [8 ]
机构：
[1] Emory Univ, Hematol Med Oncol, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA
[3] Emory Univ, Pathol, Atlanta, GA 30322 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
[6] Mem Sloan Kettering, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA
[8] Emory Univ, Winship Canc Inst, Med Oncol, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
small cell lung cancer; biomarker; SLFN11;
D O I：
10.1016/j.jtho.2018.08.1829
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12-06
引用
收藏
页码：S972 / S972
页数：1
相关论文
共 50 条
  • [1] Exploratory Analysis for Predictors of Benefit of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study
    Owonikoko, T.
    Dahlberg, S.
    Poirier, J.
    Sica, G.
    Rudin, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1766 - S1767
  • [2] Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.
    Owonikoko, Taofeek Kunle
    Dahlberg, Suzanne Eleanor
    Sica, Gabriel
    Wagner, Lynne I.
    Wade, James Lloyd
    Srkalovic, Gordan
    Lash, Bradley Walter
    Leach, Joseph W.
    Leal, Ticiana A. B.
    Aggarwal, Charu
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
    Lok, Benjamin H.
    Gardner, Eric E.
    Schneeberger, Valentina E.
    Ni, Andy
    Desmeules, Patrice
    Rekhtman, Natasha
    de Stanchina, Elisa
    Teicher, Beverly A.
    Riaz, Nadeem
    Powell, Simon N.
    Poirier, John T.
    Rudin, Charles M.
    CLINICAL CANCER RESEARCH, 2017, 23 (02) : 523 - 535
  • [4] Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
    Owonikoko, Taofeek K.
    Dahlberg, Suzanne E.
    Sica, Gabriel L.
    Wagner, Lynne, I
    Wade, James L., III
    Srkalovic, Gordan
    Lash, Bradley W.
    Leach, Joseph W.
    Leal, Ticiana B.
    Aggarwal, Charu
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 222 - +
  • [5] A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511)
    Owonikoko, Taofeek K.
    Dahlberg, Suzanne E.
    Khan, Saad A.
    Gerber, David E.
    Dowell, Jonathan
    Moss, Rebecca A.
    Belani, Chandra P.
    Hann, Christine L.
    Aggarwal, Charu
    Ramalingam, Suresh S.
    LUNG CANCER, 2015, 89 (01) : 66 - 70
  • [6] SLFN11 is a biomarker of sensitivity to PARP inhibition and chemotherapy in small cell lung cancer (SCLC)
    Stewart, C. Allison
    Tong, Pan
    Cardnell, Robert
    Sen, Triparna
    Masrorpour, Fatemah Mina
    Fan, Youhong
    Wang, Jing
    Byers, Lauren Averett
    CANCER RESEARCH, 2016, 76
  • [7] PARP inhibitor sensitivity in small cell lung cancer cell lines and patient-derived xenografts correlates with SLFN11 expression but not with structural homologous recombination deficiency
    Lok, Benjamin H.
    Feng, Ying
    Yu, G. Karen
    Gardner, Eric E.
    Riaz, Nadeem
    Ru, Yuanbin
    de Stanchina, Elisa
    Powell, Simon N.
    Shen, Jerry
    Poirier, John T.
    Rudin, Charles M.
    CANCER RESEARCH, 2016, 76
  • [8] High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models
    Gupta, Aparna
    Vaidya, Kedar S.
    Melis, Janneke J. T. M.
    Hauptschein, Robert
    Brock, Graham
    Humphreys, Robin
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
    Bingnan Zhang
    C. Allison Stewart
    Qi Wang
    Robert J. Cardnell
    Pedro Rocha
    Junya Fujimoto
    Luisa M. Solis Soto
    Runsheng Wang
    Veronica Novegil
    Peter Ansell
    Lei He
    Luisa Fernandez
    Adam Jendrisak
    Cole Gilbertson
    Joseph D. Schonhoft
    Jiyun Byun
    Joshua Jones
    Amanda K. L. Anderson
    Ana Aparicio
    Hai Tran
    Marcelo V. Negrao
    Jianjun Zhang
    Wei-lien Wang
    Ignacio I. Wistuba
    Jing Wang
    Rick Wenstrup
    Lauren A. Byers
    Carl M. Gay
    British Journal of Cancer, 2022, 127 : 569 - 576
  • [10] Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
    Zhang, Bingnan
    Stewart, C. Allison
    Wang, Qi
    Cardnell, Robert J.
    Rocha, Pedro
    Fujimoto, Junya
    Soto, Luisa M. Solis
    Wang, Runsheng
    Novegil, Veronica
    Ansell, Peter
    He, Lei
    Fernandez, Luisa
    Jendrisak, Adam
    Gilbertson, Cole
    Schonhoft, Joseph D.
    Byun, Jiyun
    Jones, Joshua
    Anderson, Amanda K. L.
    Aparicio, Ana
    Tran, Hai
    Negrao, Marcelo, V
    Zhang, Jianjun
    Wang, Wei-lien
    Wistuba, Ignacio I.
    Wang, Jing
    Wenstrup, Rick
    Byers, Lauren A.
    Gay, Carl M.
    BRITISH JOURNAL OF CANCER, 2022, 127 (03) : 569 - 576
12345